BRIC Cancer Therapeutics Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

Historic Data: 2021-2023   |   Base Year: 2024   |   Forecast Period: 2025-2031

  • Therapy Type (Chemotherapy, Targeted Therapy, Radiation Therapy, Hormone Therapy, Other Therapy Types)
  • Indications (Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Liver & Intrahepatic Bile Duct Cancer, Thyroid Cancer, Other Indications)
  • Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel)


No. of Pages: 150    |    Report Code: BMIRE00031442    |    Category: Life Sciences

BRIC Cancer Therapeutics Market
Buy Now

The cancer therapeutics market size is expected to reach US$ 80,766.61 million by 2031 from US$ 31,523.87 million in 2024. The market is estimated to record a CAGR of 13.07 % from 2025 to 2031. 

Executive Summary and BRIC Cancer Therapeutics Market Analysis:

The cancer therapeutics market in BRIC is experiencing significant growth driven by growing burden of breast and lung cancer and surging investments in oncology research. For instance, according to GLOBOCAN Statistics 2020, breast cancer caused 10.6% (90,408) of all fatalities and 13.5% (178,361) of all cancer cases in India, with a cumulative risk of 2.81. Furthermore, increasing product launches in breast cancer treatment, served by genomic approaches, targeted therapies, immunotherapies, etc., have also revolutionized the market landscape in India. These advancements have improved patient outcomes, along with creating opportunities for pharmaceutical companies to continue developing more innovative therapies. 

BRIC Cancer Therapeutics Market Strategic Insights

global-market-strategic-framework
Get more information on this report

BRIC Cancer Therapeutics Market Segmentation Analysis

Key segments that contributed to the derivation of the cancer therapeutics Market analysis are type and application.

  • By therapy type, the cancer therapeutics market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The chemotherapy segment dominated the market in 2024.
  • In terms of indications, the market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment held the largest share of the market in 2024.
  • By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment held the largest share of the market in 2024. 

BRIC Cancer Therapeutics Market Outlook

The BRIC cancer therapeutics market is segmented into Russian Federation, Brazil, South Africa, India, and China. For instance, According to GLOBOCAN 2020, there were 592,212 cancer cases across the Brazil, comprising 300,144 males and 292,098 women, and breast cancer was among the most common types. According to the Brazilian National Cancer Institute (INCA), ~66,200 new cases of breast cancer in women are diagnosed in Brazil annually. In addition, the incidence of colorectal cancer is higher among older adults; ~55,102 new colorectal cancer cases were found in Brazil in 2020, as per GLOBOCAN 2020 data.

The Brazilian government has invested in healthcare infrastructure, enabling better access to oncology services. Initiatives such as the Brazilian National Cancer Institute (INCA) have played a crucial role in enhancing cancer care and supporting research. These combined factors, along with a growing emphasis on early detection and personalized medicine, propel the expansion of the cancer therapeutics market in Brazil.

BRIC Cancer Therapeutics Market Country Insights  

Based on region, the BRIC cancer therapeutics Market is further segmented into the Russian Federation, Brazil, South Africa, India, and China. The China held the largest share in 2024.

As one of the most populous countries in the world, China is facing a growing cancer burden, and the incidence of cancer continues to rise. According to the World Health Organization (WHO), ~4.5 million new cancer cases and 3 million deaths due to cancer were reported in China in 2020. The WHO estimates indicate that approximately seven people are diagnosed with cancer and four die due to cancer in the country every minute. The most common types of cancer diagnosed are lung cancer, stomach cancer, breast cancer, thyroid cancer, and leukemia. According to a recent study named "Chronic Illness and Ageing in China," published in 2020, China's population is aging. From 2010 to 2040, it is estimated that the proportion of people aged 60 years and above in the country will rise from 12.4% (168 million) to 28% (402 million). With increasing life expectancy, the proportion of elderly people is also growing, and older adults are more susceptible to cancer.

The development of new and more effective therapies has significantly improved patient outcomes and survival rates, leading to a growing demand for these treatments. For instance, in July 2023, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) was approved in China as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Similarly, in January 2022, BeiGene, headquartered in China, won approval for Tislelizumab as a second- or third-line treatment for patients with locally advanced or metastatic non-small cell lung cancer from China National Medical Products Administration (NMPA).

BRIC Cancer Therapeutics Market Report Highlights

Report Attribute Details
Market size in 2024 US$ 31,523.87 Million
Market Size by 2031 US$ 80,766.61 Million
Global CAGR (2025 - 2031) 13.07 %
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Therapy Type
  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Hormone Therapy
  • Other Therapy Types
By Indications
  • Blood Cancer
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Cervical Cancer
  • Liver & Intrahepatic Bile Duct Cancer
  • Thyroid Cancer
  • Other Indications
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channel
Regions and Countries Covered BRIC
  • Russian Federation
  • Brazil
  • India
  • China
Get more information on this report

BRIC Cancer Therapeutics Market Company Profiles

Astellas Pharma Inc; Eli Lilly and Co; Novartis AG; Merck KGaA.; Johnson & Johnson; AstraZeneca; Pfizer Inc; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd; and AbbVie are among the key players operating in the market. These players adopt strategies such as expansion, product innovation, and mergers and acquisitions to stay competitive in the market and offer innovative products to their consumers.

BRIC Cancer Therapeutics Market Research Methodology:

The following methodology has been followed for the collection and analysis of data presented in this report:

  • Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

  • Company websites, annual reports, financial statements, broker analyses, and investor presentations
  • Industry trade journals and other relevant publications
  • Government documents, statistical databases, and market reports
  • News articles, press releases, and webcasts specific to companies operating in the market

Note:

All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

  • Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate and analyze the data and gain valuable insights. These research interviews are designed to:

  • Refine findings from secondary research
  • Enhance the expertise and market understanding of the analysis team
  • Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews with industry experts across various markets, categories, segments, and sub-segments in different regions. Participants typically include:

  • Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
  • External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

BRIC Cancer Therapeutics Market Country and Regional Insights

bric-cancer-therapeutics-market
Get more information on this report

BRIC Cancer Therapeutics Key Sources Referred:

  • The World Bank World Development Indicators
  • World Health Organization (WHO) 
  • Global Cancer Observatory 
  • Ministry of Food and Drug Safety (MFDS)
  • American Cancer Society

The List of Companies - BRIC Cancer Therapeutics Market

Frequently Asked Questions
How big is the BRIC Cancer Therapeutics Market?

The BRIC Cancer Therapeutics Market is valued at US$ 31,523.87 Million in 2024, it is projected to reach US$ 80,766.61 Million by 2031.

What is the CAGR for BRIC Cancer Therapeutics Market by (2025 - 2031)?

As per our report BRIC Cancer Therapeutics Market, the market size is valued at US$ 31,523.87 Million in 2024, projecting it to reach US$ 80,766.61 Million by 2031. This translates to a CAGR of approximately 13.07 % during the forecast period.

What segments are covered in this report?

The BRIC Cancer Therapeutics Market report typically cover these key segments-

  • Therapy Type (Chemotherapy, Targeted Therapy, Radiation Therapy, Hormone Therapy, Other Therapy Types)
  • Indications (Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Liver & Intrahepatic Bile Duct Cancer, Thyroid Cancer, Other Indications)
  • Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel)

What is the historic period, base year, and forecast period taken for BRIC Cancer Therapeutics Market?

The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the BRIC Cancer Therapeutics Market report:

  • Historic Period : 2021-2023
  • Base Year : 2024
  • Forecast Period : 2025-2031
  • Who are the major players in BRIC Cancer Therapeutics Market?

    The BRIC Cancer Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Astellas Pharma Inc
  • Eli Lilly and Co
  • Novartis AG
  • Merck KGaA
  • AstraZeneca
  • Pfizer Inc
  • Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • Who should buy this report?

    The BRIC Cancer Therapeutics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the BRIC Cancer Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.

    Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now